Laboratory test guide

Quest AD-Detect® Phosphorylated tau217 (p-tau217), Plasma

Available through Quest Diagnostics

DetailsCurrent research indicates that plasma p-tau, including p-tau 217, is concordant with amyloid status defined by either CSF biomarker testing or PET scan analysis, and is able to differentiate between AD and non-AD neurodegenerative…

Compare this test’s laboratory options

Quest AD-Detect® Phosphorylated tau217 (p-tau217), Plasma

Quest Diagnostics
1 test optionFrom $560.70View tests ↓Close ↑

Quest AD-Detect® Phosphorylated tau217 (p-tau217), Plasma

Quest Diagnostics

Details

Listed markers: pTau217, Plasma

Fasting: No

Results should be available in 2 - 5 business days after the sample is collected

Not available in: HI, PR, NJ, NY, RI

Related options may differ in markers and method; confirm with your clinician. Final prices and fees are confirmed before ordering.

SpecimenPlasma
Patient price$560.70
View →

What this laboratory test evaluates

DetailsCurrent research indicates that plasma p-tau, including p-tau 217, is concordant with amyloid status defined by either CSF biomarker testing or PET scan analysis, and is able to differentiate between AD and non-AD neurodegenerative diseases and to predict progression to AD. Blood-based biomarkers, such as plasma p-tau, could potentially be used as inclusion criteria or to evaluate target engagement and treatment efficacy, and could further advance the development of disease-modifying treatments in the field of AD and related disorders. This assay is designed specifically for the quantitative measurement of tau phosphorylated at threonine 217 (p-tau 217) in human plasma.

Test ResourcesTest FAQ: Quest Dementia Testing

Additional test information

Current research indicates that plasma p-tau, including p-tau 217, is concordant with amyloid status defined by either CSF biomarker testing or PET scan analysis, and is able to differentiate between AD and non-AD neurodegenerative diseases and to predict progression to AD. Blood-based biomarkers, such as plasma p-tau, could potentially be used as inclusion criteria or to evaluate target engagement and treatment efficacy, and could further advance the development of disease-modifying treatments in the field of AD and related disorders. This assay is designed specifically for the quantitative measurement of tau phosphorylated at threonine 217 (p-tau 217) in human plasma.

Collection and processing

  • Sample type: Plasma
  • Fasting: No
  • Estimated laboratory processing: Results should be available in 2 – 5 business days after the sample is collected

How Sunridge uses laboratory information

Sunridge considers the medical question, symptoms, history, medications, prior results, and whether the finding could change care before recommending testing. A laboratory result is not interpreted in isolation and does not establish a diagnosis by itself.

Before requesting this test

Availability, collection requirements, eligibility, and processing estimates can change. Sunridge reviews each request and, when appropriate, creates the order through Fullscript. Follow the current instructions supplied with the approved order.

About this test

DetailsCurrent research indicates that plasma p-tau, including p-tau 217, is concordant with amyloid status defined by either CSF biomarker testing or PET scan analysis, and is able to differentiate between AD and non-AD neurodegenerative diseases and to predict progression to AD. Blood-based biomarkers, such as plasma p-tau, could potentially be used as inclusion criteria or to evaluate target engagement and treatment efficacy, and could further advance the development of disease-modifying treatments in the field of AD and related disorders. This assay is designed specifically for the quantitative measurement of tau phosphorylated at threonine 217 (p-tau 217) in human plasma.

Test ResourcesTest FAQ: Quest Dementia Testing

Additional details

Current research indicates that plasma p-tau, including p-tau 217, is concordant with amyloid status defined by either CSF biomarker testing or PET scan analysis, and is able to differentiate between AD and non-AD neurodegenerative diseases and to predict progression to AD. Blood-based biomarkers, such as plasma p-tau, could potentially be used as inclusion criteria or to evaluate target engagement and treatment efficacy, and could further advance the development of disease-modifying treatments in the field of AD and related disorders. This assay is designed specifically for the quantitative measurement of tau phosphorylated at threonine 217 (p-tau 217) in human plasma.

Highlighted health areas

  • Neurological

Biomarkers and report focus

The exact analytes and report format can change. Confirm the current contents in the Fullscript order before payment.

  • pTau217, Plasma

Important laboratory-testing information

This article is educational and does not diagnose a condition, establish medical care, or replace professional advice. Test availability, contents, pricing, eligibility, specimen instructions, and processing estimates can change. Sunridge must review the request and create an appropriate Fullscript order before payment. Follow the current instructions in your Fullscript account and laboratory kit, and discuss urgent or worsening symptoms with an appropriate medical professional.

Scottsdale Clinic

14200 N Northsight Blvd #160
Scottsdale, Arizona 85260

Office Hours

Monday–Friday: 9:00 AM–5:00 PM
Saturday: 9:00 AM–12:00 PM

Visit Sunridge in Scottsdale

FREE INTRODUCTORY CALL

Speak With Our Patient Care Team

Tell us what you are facing. There is no charge to speak with our Patient Care Team, understand how Sunridge works and determine whether a physician consultation may be an appropriate next step.

Call Now: 1-800-923-7878

This introductory call is not a medical consultation and does not establish a physician-patient relationship.

Have a Question or Share Feedback:
It's easy to get in touch with us